217
Participants
Start Date
February 7, 2013
Primary Completion Date
August 23, 2016
Study Completion Date
March 9, 2021
Talimogene laherparepvec
Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
Ipilimumab
Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
Research Site, New York
Research Site, New York
Research Site, Kiel
Research Site, Chapel Hill
Research Site, Charleston
Research Site, Jacksonville
Research Site, Jacksonville
Research Site, Bordeaux
Research Site, Miami
Research Site, Lakeland
Research Site, Göttingen
Research Site, Nashville
Research Site, Grenoble
Research Site, Louisville
Research Site, Nantes
Research Site, Canton
Research Site, Cincinnati
Research Site, Indianapolis
Research Site, Indianapolis
Research Site, Iowa City
Research Site, Milwaukee
Research Site, Minneapolis
Research Site, Lille
Research Site, Chicago
Research Site, St Louis
Research Site, Tübingen
Research Site, Paris
Research Site, Houston
Research Site, Aurora
Research Site, Salt Lake City
Research Site, Tucson
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, Beverly Hills
Research Site, San Francisco
Research Site, Santa Rosa
Research Site, Los Angeles
Research Site, Morristown
Research Site, New Brunswick
Research Site, Richmond
Lead Sponsor
Amgen
INDUSTRY